Ad hoc announcement pursuant to Art. 53 LR

• Alluzience® (abobotulinumtoxinA, ABO) improves glabellar (frown) lines with high patient satisfaction
• Positive new data on the efficacy and safety of the new formulation of Sculptra® (poly-L-lactic acid, PLLA)
• Strong data from two studies showing the efficacy and safety of Galderma’s hyaluronic acid fillers

Lausanne, Switzerland, December 20^th 2019 – Galderma today announced that AKLIEF^® (trifarotene 50 mcg/g cream) has concluded its European decentralised procedure resulting in the approval of its summary of product characteristics, package leaflet, and labelling, by all involved European member states.

• Data supporting the positive decision demonstrated that patients treated with Alluzience^® for wrinkles had a rapid onset of effect starting from day one, with improvements lasting up to six months.¹

Galderma presented eight abstracts in support of innovative aesthetics solutions and pipeline, including post-marketing safety surveillance study abstract named to “Best of Cosmetic Oral Abstracts” list